Cargando…
Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018
It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 198...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907354/ https://www.ncbi.nlm.nih.gov/pubmed/35264598 http://dx.doi.org/10.1038/s41408-022-00637-1 |
_version_ | 1784665622862364672 |
---|---|
author | Durmaz, Müjde Visser, Otto Posthuma, Eduardus F. M. Brouwer, Rolf E. Issa, Djamila E. de Jong, Daphne Lam, King H. Blijlevens, Nicole M. A. Zijlstra, Josée M. Chamuleau, Martine E. D. Lugtenburg, Pieternella J. Kersten, Marie José Dinmohamed, Avinash G. |
author_facet | Durmaz, Müjde Visser, Otto Posthuma, Eduardus F. M. Brouwer, Rolf E. Issa, Djamila E. de Jong, Daphne Lam, King H. Blijlevens, Nicole M. A. Zijlstra, Josée M. Chamuleau, Martine E. D. Lugtenburg, Pieternella J. Kersten, Marie José Dinmohamed, Avinash G. |
author_sort | Durmaz, Müjde |
collection | PubMed |
description | It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II–IV disease (N = 20,676), stratified by calendar period and age (18–64, 65–74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000s, >95% of chemotherapy-treated patients received chemoimmunotherapy, irrespective of age and stage. Overall, RS increased significantly over time across all age groups, especially after 2003 when rituximab-containing chemotherapy had become the standard of care. However, RS increased less pronounced between 2003–2010 and 2011–2018 than between 1989–2002 and 2003–2010. These findings were congruent across all studied stage groups. Five-year RS across the three age groups during 2011–2018 was 96%, 84%, and 67% for stage I DLBCL and 75%, 60%, and 46% for stage II–IV DLBCL. Collectively, survival in DLBCL increased modestly beyond the initial introduction of rituximab, with apparent survival differences across age and stage that warrant novel treatment approaches. |
format | Online Article Text |
id | pubmed-8907354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-89073542022-03-23 Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 Durmaz, Müjde Visser, Otto Posthuma, Eduardus F. M. Brouwer, Rolf E. Issa, Djamila E. de Jong, Daphne Lam, King H. Blijlevens, Nicole M. A. Zijlstra, Josée M. Chamuleau, Martine E. D. Lugtenburg, Pieternella J. Kersten, Marie José Dinmohamed, Avinash G. Blood Cancer J Article It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative survival (RS) among Dutch DLBCL patients diagnosed between 1989 and 2018. Analyses were performed separately according to the stage I (N = 6952) and stage II–IV disease (N = 20,676), stratified by calendar period and age (18–64, 65–74, and ≥75 years). The use of chemotherapy ± radiotherapy increased over time across all age and stage groups. As of the mid-2000s, >95% of chemotherapy-treated patients received chemoimmunotherapy, irrespective of age and stage. Overall, RS increased significantly over time across all age groups, especially after 2003 when rituximab-containing chemotherapy had become the standard of care. However, RS increased less pronounced between 2003–2010 and 2011–2018 than between 1989–2002 and 2003–2010. These findings were congruent across all studied stage groups. Five-year RS across the three age groups during 2011–2018 was 96%, 84%, and 67% for stage I DLBCL and 75%, 60%, and 46% for stage II–IV DLBCL. Collectively, survival in DLBCL increased modestly beyond the initial introduction of rituximab, with apparent survival differences across age and stage that warrant novel treatment approaches. Nature Publishing Group UK 2022-03-09 /pmc/articles/PMC8907354/ /pubmed/35264598 http://dx.doi.org/10.1038/s41408-022-00637-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Durmaz, Müjde Visser, Otto Posthuma, Eduardus F. M. Brouwer, Rolf E. Issa, Djamila E. de Jong, Daphne Lam, King H. Blijlevens, Nicole M. A. Zijlstra, Josée M. Chamuleau, Martine E. D. Lugtenburg, Pieternella J. Kersten, Marie José Dinmohamed, Avinash G. Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title_full | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title_fullStr | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title_full_unstemmed | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title_short | Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018 |
title_sort | time trends in primary therapy and relative survival of diffuse large b-cell lymphoma by stage: a nationwide, population-based study in the netherlands, 1989–2018 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907354/ https://www.ncbi.nlm.nih.gov/pubmed/35264598 http://dx.doi.org/10.1038/s41408-022-00637-1 |
work_keys_str_mv | AT durmazmujde timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT visserotto timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT posthumaeduardusfm timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT brouwerrolfe timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT issadjamilae timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT dejongdaphne timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT lamkingh timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT blijlevensnicolema timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT zijlstrajoseem timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT chamuleaumartineed timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT lugtenburgpieternellaj timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT kerstenmariejose timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 AT dinmohamedavinashg timetrendsinprimarytherapyandrelativesurvivalofdiffuselargebcelllymphomabystageanationwidepopulationbasedstudyinthenetherlands19892018 |